1. Home
  2. OUST vs TYRA Comparison

OUST vs TYRA Comparison

Compare OUST & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ouster Inc.

OUST

Ouster Inc.

HOLD

Current Price

$21.47

Market Cap

1.0B

Sector

Technology

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$36.22

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OUST
TYRA
Founded
2015
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
OUST
TYRA
Price
$21.47
$36.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
9
Target Price
$34.80
$44.63
AVG Volume (30 Days)
1.7M
1.2M
Earning Date
01-01-0001
06-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.76
N/A
Revenue Next Year
$38.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.34
$6.42
52 Week High
$41.65
$38.00

Technical Indicators

Market Signals
Indicator
OUST
TYRA
Relative Strength Index (RSI) 51.33 63.25
Support Level $21.03 $30.10
Resistance Level $31.52 N/A
Average True Range (ATR) 1.68 2.35
MACD 0.44 0.17
Stochastic Oscillator 51.68 76.20

Price Performance

Historical Comparison
OUST
TYRA

About OUST Ouster Inc.

Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: